
Transgene ceases development of failed advanced non-squamous non-small cell lung cancer immunotherapy candidate
pharmafile | December 16, 2019 | News story | Research and Development, Sales and Marketing | Cancer, Transgene, lung cancer, pharma
Cancer immunotherapeutics firm Transgene has confirmed that it is to terminate further development of its TG4010 candidate in the first-line treatment of advanced non-squamous non-small cell lung cancer (NSCLC) after it was discovered to have failed to meet its primary endpoint at Phase 2.
Specifically, the candidate, when combined with Bristol-Myers Squibb’s Opdivo and chemotherapy, failed to achieve a clinically significant overall response rate in NSCLC patients with low-to-no expression of PD-L1 in their tumours.
The trial was conducted in partnership with BMS and examined the candidate’s efficacy in 40 UK and US patients.
“We are obviously very disappointed with the outcome of this Phase 2 trial which showed that the triple combination regimen of TG4010, chemotherapy and nivolumab did not sufficiently increase the response rate in this patient population with advanced NSCLC whose tumours express low or undetectable levels of PD-L1,” explained Dr Philippe Archinard, Chairman and CEO of Transgene. “Additional data analyses are still ongoing and the complete study results will be presented at an upcoming scientific conference.”
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

Cizzle Biotechnology expands US rollout of lung cancer blood test
Cizzle Biotechnology has launched the commercial rollout of its CIZ1B Biomarker Blood Test for lung …






